SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC boosted its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 24.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 208,160 shares of the company’s stock after purchasing an additional 40,636 shares during the period. Essex Investment Management Co. LLC owned approximately 0.50% of SI-BONE worth $2,918,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. AlphaQuest LLC raised its holdings in shares of SI-BONE by 13,950.6% during the fourth quarter. AlphaQuest LLC now owns 11,662 shares of the company’s stock valued at $164,000 after acquiring an additional 11,579 shares during the period. Raymond James Financial Inc. acquired a new position in shares of SI-BONE during the 4th quarter worth $1,233,000. Proficio Capital Partners LLC bought a new stake in shares of SI-BONE during the 4th quarter worth $155,000. Mainstream Capital Management LLC bought a new stake in shares of SI-BONE during the 4th quarter worth $53,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of SI-BONE by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company’s stock worth $4,504,000 after buying an additional 6,171 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

SI-BONE Stock Down 1.8 %

Shares of NASDAQ SIBN opened at $16.06 on Friday. The firm has a market capitalization of $681.80 million, a PE ratio of -17.46 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $19.16. The firm’s 50-day moving average is $16.44 and its 200-day moving average is $14.89.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $49.00 million for the quarter, compared to analyst estimates of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now owns 222,814 shares of the company’s stock, valued at $3,097,114.60. This trade represents a 1.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at $2,633,427.29. The trade was a 2.73 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,311 shares of company stock valued at $130,356. 3.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on SIBN shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Needham & Company LLC increased their target price on shares of SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Truist Financial reiterated a “buy” rating and set a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $24.50.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.